In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Is HTA going to save health care budgets or are its premises inherently flawed?

This article was originally published in Clinica

Executive Summary

Does the very nature of health technology assessment point the finger of blame for soaring medical costs at the healthcare industry? Is it time to challenge the scope of HTA and call for comparative studies of all healthcare interventions so that the real value of medical technology is more accurately understood in the overall healthcare framework? These are questions on the mind of Miro Palat, president of CzechMed, the Czech medical device industry association






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts